Dean B, Bakker G, Ueda H, Tobin A, Brown A, Kanaan R
Front Cell Neurosci. 2023; 17:1124333.
PMID: 36909280
PMC: 9992992.
DOI: 10.3389/fncel.2023.1124333.
Stuke H
Front Psychiatry. 2023; 13:1100030.
PMID: 36699495
PMC: 9868756.
DOI: 10.3389/fpsyt.2022.1100030.
Fujita M, Ochiai Y, Hagino Y, Kobayashi K, Pavey G, Dean B
Mol Brain. 2022; 15(1):96.
PMID: 36447257
PMC: 9710075.
DOI: 10.1186/s13041-022-00984-x.
Weber L, Tomiello S, Schobi D, Wellstein K, Mueller D, Iglesias S
Elife. 2022; 11.
PMID: 35502897
PMC: 9098218.
DOI: 10.7554/eLife.74835.
Dean B, Scarr E
NPJ Schizophr. 2021; 7(1):44.
PMID: 34521861
PMC: 8440523.
DOI: 10.1038/s41537-021-00174-z.
Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
Avram M, Grothe M, Meinhold L, Leucht C, Leucht S, Borgwardt S
Neuropsychopharmacology. 2021; 46(13):2320-2329.
PMID: 34188186
PMC: 8580980.
DOI: 10.1038/s41386-021-01070-x.
The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.
Boczek T, Mackiewicz J, Sobolczyk M, Wawrzyniak J, Lisek M, Ferenc B
Cells. 2021; 10(5).
PMID: 34067760
PMC: 8155952.
DOI: 10.3390/cells10051228.
Functional coupling of M muscarinic acetylcholine receptor to Gα in dorsolateral prefrontal cortex from patients with psychiatric disorders: a postmortem study.
Odagaki Y, Kinoshita M, Meana J, Callado L, Garcia-Sevilla J
Eur Arch Psychiatry Clin Neurosci. 2019; 270(7):869-880.
PMID: 31807862
DOI: 10.1007/s00406-019-01088-9.
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia.
Hopper S, Pavey G, Gogos A, Dean B
Int J Neuropsychopharmacol. 2019; 22(10):640-650.
PMID: 31428788
PMC: 6822142.
DOI: 10.1093/ijnp/pyz045.
Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia.
Scarr E, Hopper S, Vos V, Seo M, Everall I, Aumann T
J Psychiatry Neurosci. 2018; 43(5):338-346.
PMID: 30125244
PMC: 6158028.
Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia.
Gibbons A, Udawela M, Dean B
Noncoding RNA. 2018; 4(2).
PMID: 29657307
PMC: 6027250.
DOI: 10.3390/ncrna4020011.
Cognitive burden of anticholinergic medications in psychotic disorders.
Eum S, Hill S, Rubin L, Carnahan R, Reilly J, Ivleva E
Schizophr Res. 2017; 190:129-135.
PMID: 28390849
PMC: 5628100.
DOI: 10.1016/j.schres.2017.03.034.
Muscarinic receptor binding changes in postmortem Parkinson's disease.
McOmish C, Pavey G, McLean C, Horne M, Dean B, Scarr E
J Neural Transm (Vienna). 2016; 124(2):227-236.
PMID: 27873015
DOI: 10.1007/s00702-016-1629-z.
Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia.
Dean B, Thomas N, Scarr E, Udawela M
Transl Psychiatry. 2016; 6(11):e949.
PMID: 27845781
PMC: 5314134.
DOI: 10.1038/tp.2016.226.
Histamine H receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective.
Mahmood D
Int J Health Sci (Qassim). 2016; 10(4):564-575.
PMID: 27833522
PMC: 5085352.
Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor.
Scarr E, Udawela M, Thomas E, Dean B
Mol Psychiatry. 2016; 23(2):295-303.
PMID: 27801890
PMC: 5794886.
DOI: 10.1038/mp.2016.195.
Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.
Scarr E, McLean C, Dean B
J Neural Transm (Vienna). 2016; 124(3):273-284.
PMID: 27688247
DOI: 10.1007/s00702-016-1625-3.
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M PAM VU6004256.
Grannan M, Mielnik C, Moran S, Gould R, Ball J, Lu Z
ACS Chem Neurosci. 2016; 7(12):1706-1716.
PMID: 27617634
PMC: 5231396.
DOI: 10.1021/acschemneuro.6b00230.
Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.
Dean B, Hopper S, Conn P, Scarr E
Neuropsychopharmacology. 2015; 41(6):1620-8.
PMID: 26511338
PMC: 4832025.
DOI: 10.1038/npp.2015.330.
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
Gibbons A, Jeon W, Scarr E, Dean B
Int J Neuropsychopharmacol. 2015; 19(4).
PMID: 26475745
PMC: 4851264.
DOI: 10.1093/ijnp/pyv118.